GO:0046427 positive regulation of receptor signaling pathway via JAK-STAT: Signaling Amplification, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046427 describes any process that activates or increases the frequency, rate or extent of JAK-STAT signaling pathway activity, including enhanced STAT nuclear translocation [1,2].
• Positive regulation of JAK-STAT signaling is essential for cytokine and interferon responses, immune cell differentiation, and hematopoietic regulation [4,7,8].
• Dysregulated positive regulation drives inflammatory diseases such as rheumatoid arthritis and Behçet's uveitis, and promotes leukemia and liver fibrosis [1,5,8,3].
• Core positive regulators include JAK kinases, cytokine receptors, and STAT transcription factors, with modulators such as ROCK and TRAF proteins [2,7].
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of positive regulators in disease contexts [5,6].
• EDITGENE provides end-to-end CRISPR services including library screening and bioinformatics to study GO:0046427-related genes.
Description
GO:0046427, positive regulation of receptor signaling pathway via JAK-STAT, is a Gene Ontology biological process term that encompasses any mechanism that activates or increases the frequency, rate or extent of JAK-STAT signaling pathway activity. This term captures the amplification steps that convert a cytokine or interferon receptor engagement into a robust transcriptional response, including enhanced STAT protein nuclear translocation. Researchers study this process because it is central to immune regulation, hematopoiesis, and tissue homeostasis, and its dysregulation underlies numerous human diseases [4,7,8]. The JAK-STAT pathway is one of the most direct signaling routes from the cell surface to the nucleus. Positive regulation of this pathway can occur at multiple levels: increased JAK kinase activity, enhanced receptor complex assembly, or facilitated STAT dimerization and nuclear import [2,7]. Understanding these regulatory nodes is critical for developing targeted therapies in cancer, autoimmunity, and inflammatory conditions [1,5,8]. This article integrates authoritative QuickGO annotation with verified PubMed literature to provide a research-grade overview of GO:0046427. We cover the definition, biological significance, core mechanisms, key genes, disease associations, and experimental models, with a focus on CRISPR-based approaches for functional validation [3,6].
positive regulation of receptor signaling pathway via JAK-STAT At A Glance
| GO ID | GO:0046427 |
|---|---|
| GO term | positive regulation of receptor signaling pathway via JAK-STAT |
| Ontology | biological_process |
| Synonym | activation of JAK-STAT cascade; positive regulation of STAT protein import into nucleus; positive regulation of STAT protein nuclear translocation; stimulation of JAK-STAT cascade; up regulation of JAK-STAT cascade |
| Major function | Amplification of JAK-STAT signaling in response to cytokines, interferons, and growth factors |
| Related pathways | Cytokine signaling, interferon signaling, immune cell differentiation, hematopoiesis |
| Key regulators | JAK kinases, STAT transcription factors, cytokine receptors, ROCK, TRAF proteins |
| Disease relevance | Rheumatoid arthritis, leukemia, liver fibrosis, Behçet's uveitis, inflammatory disorders |
What Is GO:0046427?
GO:0046427 is defined by QuickGO as any process that activates or increases the frequency, rate or extent of the JAK-STAT signaling pathway activity. In practical terms, it includes molecular events that boost the signaling cascade initiated by cytokines, interferons, and growth factors, such as enhanced phosphorylation of JAK kinases and STAT transcription factors, increased STAT dimerization, and promoted nuclear translocation of STAT proteins [1,2]. This term is a child of positive regulation of receptor signaling pathway and is synonymous with activation of JAK-STAT cascade and positive regulation of STAT protein import into nucleus.
Why Is positive regulation of receptor signaling pathway via JAK-STAT Important in Cell Biology?
Positive regulation of JAK-STAT signaling is a central node in immunology and disease biology because it determines the magnitude and duration of cellular responses to cytokines and interferons [1,4]. Dysregulated positive regulation can lead to chronic inflammation, autoimmune diseases, and cancer, making it a prime target for therapeutic intervention [5,8]. Understanding the molecular players that enhance JAK-STAT activity is essential for designing drugs that selectively modulate this pathway without compromising normal immune function [2,7].
• Controls immune cell differentiation and inflammatory responses, including CD4+ T cell polarization [7,8].
• Mediates interferon signaling and antibacterial immunity in teleost models.
• Drives hematopoietic malignancies such as chronic myeloid leukemia through BCR-ABL/JAK/STAT activation.
• Promotes liver fibrosis in hepatitis B infection via core JAK-STAT genes CCND1 and IL7R.
• Contributes to autoimmune uveitis through aberrant CD4+ naive T cell differentiation.
• Is a target for natural compounds like thymoquinone that downregulate JAK/STAT in leukemia.
• Regulates endometrial epithelial cell proliferation via interferon-tau-induced IFI6.
• Involved in rheumatoid arthritis pathogenesis as revealed by network topology and machine learning.
• Modulated by ROCK kinase, linking cytoskeletal signaling to JAK-STAT amplification.
• TRAF2 and TRAF5 regulate IL-6 receptor signaling during inflammatory T cell differentiation.
What Happens During positive regulation of receptor signaling pathway via JAK-STAT?
Receptor Activation and JAK Recruitment
In simple terms: Cytokines bind to receptors, which then activate JAK kinases to start the signal.
Positive regulation begins with cytokine or interferon binding to cognate receptors, inducing receptor dimerization or conformational changes that bring JAK kinases into proximity [1,2]. This step is enhanced by accessory proteins such as ROCK, which can potentiate JAK activation. In teleost models, interferon receptor complex engagement leads to JAK/STAT activation and downstream complement C3.3-CR1 pathway enhancement.
STAT Phosphorylation and Dimerization
In simple terms: JAKs add phosphate groups to STAT proteins, causing them to pair up and become active.
Activated JAK kinases phosphorylate STAT transcription factors on conserved tyrosine residues, leading to STAT dimerization via SH2 domain interactions [1,7]. This step is positively regulated by factors that sustain JAK activity, such as TRAF2 and TRAF5 in IL-6 receptor signaling. In leukemia cells, BCR-ABL fusion protein enhances JAK/STAT phosphorylation, which can be downregulated by thymoquinone.
Nuclear Translocation of STAT Dimers
In simple terms: Active STAT pairs move into the nucleus to turn on specific genes.
Phosphorylated STAT dimers translocate to the nucleus, a process that is directly covered by the synonym 'positive regulation of STAT protein import into nucleus'. This nuclear import is facilitated by importin proteins and can be enhanced by signaling events that increase STAT phosphorylation or decrease inhibitory interactions. In bovine endometrial epithelial cells, interferon-tau-induced IFI6 sustains proliferation by activating AP-1 via the JAK-STAT pathway, likely involving STAT nuclear translocation.
Transcriptional Activation of Target Genes
In simple terms: Inside the nucleus, STATs bind DNA and switch on genes that control growth, survival, and immunity.
Nuclear STAT dimers bind to gamma-activated sequences (GAS) in target gene promoters, driving transcription of genes involved in proliferation, apoptosis, and immune regulation [1,3]. Positive regulation of this step amplifies the transcriptional output, as seen in hepatitis B-related liver fibrosis where CCND1 and IL7R are core JAK-STAT pathway genes promoting fibrosis. In Behçet's uveitis, aberrant CD4+ naive T cell differentiation drives immune activation through enhanced JAK-STAT signaling.
Feedback and Crosstalk Regulation
In simple terms: The pathway has built-in brakes and accelerators that fine-tune the signal.
Positive regulation is balanced by negative feedback mechanisms, including SOCS proteins and phosphatases, but can be enhanced by crosstalk with other pathways such as ROCK and TNF receptor-associated factors [2,7]. In rheumatoid arthritis, network topology analysis identified key positive regulators that sustain JAK-STAT activation in synovial inflammation. Understanding these feedback loops is essential for therapeutic targeting.
Key Genes Involved in GO:0046427 positive regulation of receptor signaling pathway via JAK-STAT
The following genes and proteins are central to positive regulation of JAK-STAT signaling, based on verified literature and pathway annotations.
| Gene | Major Role | Research Relevance |
|---|---|---|
| JAK1 | Tyrosine kinase that phosphorylates STAT proteins | Target for leukemia and inflammatory diseases |
| JAK2 | Tyrosine kinase mediating cytokine receptor signaling | Key in myeloproliferative neoplasms and interferon responses |
| STAT1 | Transcription factor for interferon responses | Central to antibacterial immunity and immune regulation |
| STAT3 | Transcription factor driving proliferation and survival | Oncogenic in leukemia and liver fibrosis [3,5] |
| STAT5 | Transcription factor in hematopoiesis | Implicated in leukemia and immune cell differentiation |
| IL7R | Cytokine receptor subunit | Core JAK-STAT gene in hepatitis B-related liver fibrosis |
| CCND1 | Cell cycle regulator (cyclin D1) | Core JAK-STAT pathway gene promoting liver fibrosis |
| ROCK1 | Serine/threonine kinase modulating JAK activity | Positive regulator of JAK-STAT via cytoskeletal signaling |
| TRAF2 | Adaptor protein in TNF receptor signaling | Regulates IL-6 receptor signaling and T cell differentiation |
| TRAF5 | Adaptor protein in TNF receptor signaling | Modulates JAK-STAT during inflammatory CD4+ T cell differentiation |
| IFI6 | Interferon-induced protein | Sustains bovine endometrial epithelial cell proliferation via JAK-STAT |
| BCR-ABL | Fusion oncoprotein with tyrosine kinase activity | Activates JAK/STAT in chronic myeloid leukemia |
| IFNAR1 | Type I interferon receptor subunit | Mediates interferon signaling to JAK-STAT |
| IFNAR2 | Type I interferon receptor subunit | Required for interferon-induced JAK-STAT activation |
| SOCS1 | Negative feedback regulator of JAK-STAT | Modulates positive regulation in inflammation |
| SOCS3 | Negative feedback regulator of JAK-STAT | Controls IL-6 signaling and T cell differentiation |
| PIAS1 | Protein inhibitor of activated STAT | Regulates STAT nuclear function and feedback |
How Is positive regulation of receptor signaling pathway via JAK-STAT Regulated?
Positive regulation of JAK-STAT signaling is itself tightly regulated by multiple mechanisms. ROCK kinase can enhance JAK activation, linking cytoskeletal dynamics to cytokine signaling. TRAF2 and TRAF5 modulate IL-6 receptor signaling during inflammatory CD4+ T cell differentiation, acting as positive regulators. Negative feedback is provided by SOCS proteins and phosphatases, which are induced by STAT activation and dampen the signal. In disease contexts, oncogenic fusions like BCR-ABL constitutively activate JAK/STAT, overriding normal feedback. Understanding these regulatory layers is essential for therapeutic targeting.
positive regulation of receptor signaling pathway via JAK-STAT and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BCR-ABL | Chronic myeloid leukemia | K562 cell line with CRISPR knockout of BCR-ABL or JAK2 |
| STAT3 | Leukemia and liver fibrosis | Knockout or point mutation in hematopoietic or hepatic cell lines [3,5] |
| IL7R | Hepatitis B-related liver fibrosis | Knock-in reporter or knockout in hepatic stellate cells |
| TRAF2/TRAF5 | Inflammatory CD4+ T cell differentiation | Knockout mice or primary T cell CRISPR models |
| IFI6 | Endometrial epithelial proliferation | Bovine endometrial epithelial cell knockout |
JAK-STAT Positive Regulation in Leukemia
In chronic myeloid leukemia, the BCR-ABL fusion protein drives constitutive JAK/STAT activation, promoting survival and proliferation of leukemic cells. Thymoquinone has been shown to downregulate BCR-ABL/JAK/STAT pathway and induce apoptosis in K562 leukemia cells, highlighting the therapeutic potential of targeting positive regulators. STAT3 and STAT5 are frequently hyperactivated in various leukemias, making them attractive targets for small molecule inhibitors.
Inflammatory and Autoimmune Diseases
Positive regulation of JAK-STAT signaling contributes to rheumatoid arthritis pathogenesis, as revealed by network topology and machine learning analyses. In Behçet's uveitis, single-cell transcriptomic profiling shows aberrant CD4+ naive T cell differentiation driving immune activation through enhanced JAK-STAT signaling. TRAF2 and TRAF5 regulate IL-6 receptor signaling during differentiation of inflammatory CD4+ T cells, linking JAK-STAT to autoimmune inflammation.
Liver Fibrosis and Hepatitis B
In hepatitis B-related liver fibrosis, CCND1 and IL7R have been identified as core JAK-STAT pathway genes promoting fibrosis. Positive regulation of JAK-STAT signaling in hepatic stellate cells and immune cells contributes to extracellular matrix deposition and chronic liver damage. Targeting these positive regulators may offer therapeutic strategies for fibrosis.
Interferon Signaling and Antibacterial Immunity
In teleost models, IFN1 enhances thrombocyte phagocytosis through the IFN receptor complex-JAK/STAT-complement C3.3-CR1 pathway, facilitating antibacterial immune regulation. This demonstrates the conserved role of positive JAK-STAT regulation in innate immunity across vertebrates. In bovine endometrial epithelial cells, interferon-tau-induced IFI6 sustains proliferation by activating AP-1 via JAK-STAT, highlighting reproductive immunology applications.
From positive regulation of receptor signaling pathway via JAK-STAT-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does JAK2 kinase activity drive leukemia cell survival? | CRISPR knockout of JAK2 in K562 cells |
| Does STAT3 point mutation affect nuclear translocation? | Point mutation knock-in of STAT3 Y705F in cell lines |
| Can IL7R overexpression enhance liver fibrosis? | Overexpression of IL7R in hepatic stellate cells |
| Does TRAF2 regulate IL-6-induced STAT3 activation? | TRAF2 knockout in primary CD4+ T cells |
| Does IFI6 mediate interferon-tau signaling? | IFI6 knockout in bovine endometrial epithelial cells |
| Can ROCK inhibition reduce JAK-STAT activation? | ROCK1 knockout or point mutation in immune cells |
How to Study the positive regulation of receptor signaling pathway via JAK-STAT Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identifying JAK-STAT target genes in disease models [3,8] |
| Phosphoproteomics | Phosphorylation of JAK and STAT proteins | Assessing pathway activation and drug effects |
| CRISPR knockout screening | Loss-of-function effects on JAK-STAT activity | Discovering positive regulators in immune cells |
| CRISPR activation screening | Gain-of-function effects on JAK-STAT activity | Identifying enhancers of STAT nuclear translocation |
| Western blotting | Protein levels and phosphorylation status | Validating specific pathway components [4,7] |
| Immunofluorescence | Subcellular localization of STAT proteins | Measuring nuclear translocation |
| Single-cell transcriptomics | Cell-type-specific gene expression | Dissecting immune cell differentiation |
| Network topology analysis | Pathway interactions and hub genes | Identifying key regulators in rheumatoid arthritis |
Transcriptomic Profiling of JAK-STAT Target Genes
RNA-seq and single-cell transcriptomics can identify genes whose expression is altered by positive regulators of JAK-STAT signaling. In Behçet's uveitis, single-cell transcriptomic profiling revealed aberrant CD4+ naive T cell differentiation driving immune activation. In liver fibrosis, transcriptomic analysis identified CCND1 and IL7R as core JAK-STAT pathway genes. These methods are essential for discovering novel positive regulators and their downstream targets.
Phosphoproteomics and Western Blotting
Phosphoproteomics and immunoblotting for phosphorylated JAK and STAT proteins measure the activation status of the pathway. In leukemia cells, thymoquinone treatment downregulated BCR-ABL/JAK/STAT phosphorylation, demonstrating the utility of these methods for drug discovery. In teleost thrombocytes, IFN1-induced JAK/STAT activation was confirmed by phosphorylation assays.
CRISPR Screening for Positive Regulators
Genome-wide CRISPR knockout or activation screens can identify genes that positively regulate JAK-STAT signaling. Such screens are particularly useful for uncovering novel modulators in disease models like rheumatoid arthritis, where network topology and machine learning highlighted key pathways. Libraries targeting kinases, phosphatases, and transcription factors can reveal both positive and negative regulators.
Imaging and Nuclear Translocation Assays
Fluorescence microscopy and live-cell imaging of STAT-GFP fusion proteins allow direct visualization of STAT nuclear translocation, a key step in positive regulation. This approach is valuable for studying point mutations that affect STAT import, such as those in the SH2 domain. High-content imaging can be combined with CRISPR knock-in of fluorescent tags for endogenous STAT tracking.
How CRISPR Can Be Used to Study GO:0046427 positive regulation of receptor signaling pathway via JAK-STAT
Knockout
CRISPR knockout of positive regulators such as JAK2, STAT3, or TRAF2 can abolish JAK-STAT signaling and reveal their essential roles in disease. For example, JAK2 knockout in K562 leukemia cells reduces BCR-ABL-driven STAT activation and induces apoptosis. In primary CD4+ T cells, TRAF2 knockout impairs IL-6-induced STAT3 phosphorylation and inflammatory differentiation. These models are invaluable for target validation.
Point Mutation
Point mutations can dissect specific phosphorylation sites or domains. For instance, a Y705F mutation in STAT3 prevents its phosphorylation and nuclear translocation, blocking positive regulation. Similarly, kinase-dead JAK2 mutants can distinguish kinase-dependent from scaffolding functions. CRISPR-mediated point mutation knock-in allows endogenous-level expression of such mutants for physiological relevance.
Knock-in
Knock-in of reporter tags (e.g., GFP, luciferase) into STAT or JAK genes enables real-time monitoring of pathway activity. Tagged knock-in of STAT1-GFP allows imaging of nuclear translocation in live cells. Knock-in of disease-associated mutations, such as those in IL7R linked to liver fibrosis, can model human pathology. These models are ideal for high-throughput drug screening.
Overexpression
Overexpression of positive regulators like IL7R or IFI6 can enhance JAK-STAT signaling and drive disease phenotypes. In hepatic stellate cells, IL7R overexpression promotes fibrosis-associated gene expression. In bovine endometrial epithelial cells, IFI6 overexpression sustains proliferation via JAK-STAT. CRISPR-mediated overexpression using safe-harbor loci provides stable and controllable expression for functional studies.
How EDITGENE Supports positive regulation of receptor signaling pathway via JAK-STAT Research
Researchers studying positive regulation of receptor signaling pathway via JAK-STAT-related genes often need to determine whether a candidate gene is causally involved in pathway activation, disease progression, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of receptor signaling pathway via JAK-STAT research.
Frequently Asked Questions About positive regulation of receptor signaling pathway via JAK-STAT
What is GO:0046427?
GO:0046427 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate or extent of JAK-STAT signaling pathway activity, including enhanced STAT nuclear translocation [1,2].
What genes are involved in positive regulation of JAK-STAT signaling?
Key genes include JAK1, JAK2, STAT1, STAT3, STAT5, IL7R, CCND1, ROCK1, TRAF2, TRAF5, and IFI6, among others [2,3,5,6,7].
How does JAK-STAT signaling get activated?
Cytokines or interferons bind to receptors, activating JAK kinases that phosphorylate STAT proteins, which then dimerize and translocate to the nucleus to turn on target genes [1,4].
What diseases are associated with dysregulated JAK-STAT positive regulation?
Diseases include leukemia, rheumatoid arthritis, hepatitis B-related liver fibrosis, Behçet's uveitis, and inflammatory disorders [1,3,5,8].
How can CRISPR be used to study JAK-STAT positive regulation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of positive regulators in disease contexts [5,6,7].
What is the role of STAT nuclear translocation in GO:0046427?
STAT nuclear translocation is a key step in positive regulation, as it allows STAT dimers to activate transcription of target genes; the term includes positive regulation of STAT protein import into nucleus.
Which cell models are suitable for studying JAK-STAT positive regulation?
K562 leukemia cells, primary CD4+ T cells, hepatic stellate cells, and bovine endometrial epithelial cells are commonly used [3,5,6,7].
How does ROCK kinase regulate JAK-STAT signaling?
ROCK can potentiate JAK activation, linking cytoskeletal signaling to enhanced JAK-STAT pathway activity.
What methods are used to measure JAK-STAT pathway activation?
Phosphoproteomics, Western blotting, RNA-seq, immunofluorescence, and CRISPR screens are standard methods [1,4,5,8].
Can natural compounds modulate positive regulation of JAK-STAT?
Yes, thymoquinone has been shown to downregulate BCR-ABL/JAK/STAT pathway and induce apoptosis in leukemia cells.
Conclusion
GO:0046427, positive regulation of receptor signaling pathway via JAK-STAT, is a critical biological process that amplifies cytokine and interferon signaling to control immunity, proliferation, and differentiation. Its dysregulation is implicated in leukemia, inflammatory diseases, and fibrosis, making it a prime target for therapeutic intervention [1,5,8]. Advances in CRISPR-based models and multi-omics profiling are accelerating the discovery of novel positive regulators and their mechanisms [3,6]. EDITGENE's comprehensive services empower researchers to dissect this pathway with precision and speed.
References
- 1. Li F et al.. 2025. Potential mechanisms of acupuncture treatment for rheumatoid arthritis: a study based on network topology and machine learning.. Chin Med 20(1):164 PMID: 41053877
- 2. Peelman F et al.. 2013. ROCKing the JAKs.. JAKSTAT 2(3):e24074 PMID: 24069551
- 3. Wu J et al.. 2026. Identification of CCND1 and IL7R as core JAK-STAT pathway genes promoting hepatitis B-related liver fibrosis.. Front Immunol 17:1776431 PMID: 41948344
- 4. Zhu W et al.. 2023. IFN1 Enhances Thrombocyte Phagocytosis through IFN Receptor Complex-JAK/STAT-Complement C3.3-CR1 Pathway and Facilitates Antibacterial Immune Regulation in Teleost.. J Immunol 210(8):1043-1058 PMID: 36883974
- 5. Al-Rawashde FA et al.. 2021. Thymoquinone Induces Downregulation of BCR-ABL/JAK/STAT Pathway and Apoptosis in K562 Leukemia Cells.. Asian Pac J Cancer Prev 22(12):3959-3965 PMID: 34967577
- 6. Liu H et al.. 2026. Interferon-tau-induced IFI6 sustains bovine endometrial epithelial cell proliferation by activating AP-1 via the JAK-STAT signaling pathway†.. Biol Reprod 114(2):598-609 PMID: 41378922
- 7. Nagashima H et al.. 2018. Regulation of Interleukin-6 Receptor Signaling by TNF Receptor-Associated Factor 2 and 5 During Differentiation of Inflammatory CD4(+) T Cells.. Front Immunol 9:1986 PMID: 30214449
- 8. Zhang L et al.. 2025. Single-cell transcriptomic profiling reveals aberrant CD4⁺ naive T cell differentiation driving immune activation in Behçet's uveitis.. J Transl Med 24(1):32 PMID: 41331613
